The executive of a private health group has expressed disappointment that a planned inquiry into South Africa’s private healthcare market by the Competition Commission will not also umbrella the pharmaceutical sector. Netcare CEO Richard Friedland offered the remarks on Monday, noting that consumers pay “40 percent more” for drugs in South Africa. The Commission’s planned review of the healthcare market will bring private hospitals and medical schemes under a close watch but appears to let the pharmaceutical sector off the hook under the argument that pharmaceutical prices are already regulated. Further, Friedland said the allowance of parallel imports of drugs could help lower costs for consumers. Netcare is currently the nation’s third-largest private hospital group.
Featured News
Beumer Challenges EU Decision on Vanderlande-Siemens Merger Review
Jul 26, 2026 by
CPI
China Fines Trip.com US$765 Million in Major Antitrust Enforcement Action
Jul 26, 2026 by
CPI
House Judiciary Panel Launches Antitrust Inquiry Into Compass and MRED
Jul 26, 2026 by
CPI
Paramount Delays Warner Bros. Discovery Merger Until Antitrust Case Moves Forward
Jul 26, 2026 by
CPI
Judge Pushes Elite College Financial Aid Antitrust Trial Toward Thanksgiving Finish
Jul 23, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes